Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 13/20 | 0.67 |
| ▸ | HTR7 | P34969 | 8/20 | 0.67 |
| ▸ | DRD2 | P14416 | 4/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5655873 | 0.94 | HTR1A (0.72) | HTR1AHTR7DRD2KCNH2MEN1 | |
| SCHEMBL5659607 | 0.88 | HTR1A (0.60) | HTR1AHTR7DRD2CACNA1GSMN1; SMN2 | |
| SCHEMBL5655898 | 0.84 | DRD2 (0.61) | HTR1AHTR7DRD2KCNH2CACNA1G | |
| SCHEMBL4636850 | 0.82 | HTR1A (0.69) | HTR1AHTR7DRD2MEN1KMT2A | |
| SCHEMBL5657585 | 0.82 | HTR1A (0.55) | HTR1AHTR7DRD2CACNA1GSMN1; SMN2 | |
| SCHEMBL4684303 | 0.81 | HTR1A (0.62) | HTR1AHTR7DRD2KCNH2CACNA1G | |
| SCHEMBL5657775 | 0.81 | DRD2 (0.62) | HTR1AHTR7DRD2KCNH2CACNA1G | |
| SCHEMBL8267294 | 0.81 | HTR1A (0.61) | HTR1AHTR7DRD2CACNA1G | |
| SCHEMBL5655720 | 0.80 | HTR1A (0.69) | HTR1AHTR7DRD2CACNA1GALDH1A1 | |
| SCHEMBL4684256 | 0.80 | HTR1A (0.58) | HTR1AHTR7DRD2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223765-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| US-7074796-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-11 | — | — | US | disclosed |
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-06 | — | — | US | disclosed |
| EP-1464641-A1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | H. Lundbeck A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| EP-1246817-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049679-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | OPRD1, VDR, GPR4 | HTR1A 331/4885HTR7 217/4885DRD2 27/4885 |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | OPRD1, DRD3, DRD2 | HTR1A 81/4885HTR7 32/4885DRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.